Tiziana Life Sciences – Phase 1b/2 Clinical Trial – Crohn’s Disease November 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

11th November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Phase 1b/2 Clinical Trial – Crohn’s Disease Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody – Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease -Crohn’s Disease Therapeutics Market Size $4.7 Billion by…

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sci PLC (TILS) Change of Adviser July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited. For further enquiries: Tiziana Life Sciences plc +44 (0)20 7493 2853 Gabriele Cerrone, Chairman and founder …

Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note…

Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3 Tiziana’s…

Tiziana Life Sciences – Phase 1b/2 Clinical Trial – Crohn’s Disease November 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci PLC (TILS) Change of Adviser July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL